1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Acusphere, Inc.

Acusphere, Inc.

ACUS
Acusphere, Inc.US flagOther OTC
0.00
USD
- -
- -
49.00Market Cap
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
TTM
Revenue per Share
- -
- -
- -
- -
1.1
1.81
0.65
0.63
0.54
Basic EPS, GAAP
-642.31
-507.78
-271.29
-66.56
-19.2
-24.89
-23
-13.14
-10.44
Free Cash Flow per Basic Share
- -
- -
-227.59
-38.31
-20.19
-33.69
-17.82
-10.02
-6.09
Dividend per Share
- -
- -
- -
- -
- -
1.17
0.86
0.53
0.12
Book Value per Share
- -
- -
-1,456.85
-347.03
-112.32
-116.33
-101.73
-78.45
-78.91
Tangible Book Value per Share
-1,435.65
-1,785.26
-1,057.45
129.85
29.17
30.38
21.18
5.57
-2.21
Basic Weighted Avg Shares
- -
- -
- -
- -
2
2
3
4
5
Sales/Revenue/Turnover
- -
- -
- -
- -
2
3
2
3
3
Operating Margin (%)
- -
- -
- -
- -
-1,775.26
-1,346.63
-3,496.86
-1,977.02
-1,837.44
Depreciation Expense
- -
- -
2
2
1
4
10
8
10
Net Income, GAAP
-24
-18
-22
-22
-30
-45
-61
-54
-47
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-1,747.9
-1,301.4
-3,430.04
-2,014.62
-1,874.95
Working Capital
- -
- -
3
51
34
31
38
9
-14
LT Debt
- -
- -
2
- -
3
15
9
9
3
Total Equity
-64
-86
-85
54
46
57
58
24
-10
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
10
11
10
LT Borrowings
7
4
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
21
32
16

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
26
14
6
Cash, Cash Equivalents & STI
25
12
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
21
21
20
Payables & Accruals
6
5
5
ST Debt
10
11
10
Deferred Revenue
5
3
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-42.29%
-59.38%
Free Cash Flow
- -
29.97%
-13.17%
Net Income, GAAP
- -
22.11%
-12.05%
Sales/Revenue/Turnover
- -
- -
49.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
1
- -
- -
1
2
2007
1
1
1
1
3
2008
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-6.14
-8.37
-4.63
- -
-23
2007
-3.44
-3.81
-3.15
- -
-13.14
2008
-2.9
-2.48
-2.26
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
0.26
0.21
0.21
- -
0.86
2007
0.16
0.14
0.12
- -
0.53
2008
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
William I. Ramage D.Phil
Full Time Employees
50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
500 Arsenal Street Watertown MA United States of America 02472
IPO Date
Oct 8, 2003
CIK
0001115143
Website
acusphere.com
Similar Companies
THC Biomed Intl Ltd. (THCBF)
Haemato AG (HAEK.DE)
High Sierra Technologies, Inc. (HSTI)
Pacira BioSciences, Inc. (PCRX)
Panaxia Labs Israel Ltd (PNAX.TA)
HLB Pharmaceutical Co., Ltd (047920.KQ)
Business
Acusphere, Inc. operates as a specialty pharmaceutical company primarily engaged in the development and commercialization of cardiovascular drugs. The company's principal product is Imagify, an injectable suspension containing perflubutane polymer microspheres designed for myocardial perfusion imaging to detect coronary artery disease. Imagify serves as a diagnostic tool offering a radiation-free alternative to nuclear stress testing. Acusphere also leverages proprietary microsphere technology to develop new drugs and improved formulations of existing drugs, focusing on enhancing safety, efficacy, and patient compliance. The company operates mainly in the United States with regulatory and commercial development efforts in the European Union, having submitted a Marketing Authorization Application for Imagify to the European Medicines Agency. Founded in 1993, Acusphere is headquartered in Watertown, Massachusetts. In recent years, Acusphere has focused on strategic partnerships, notably with Cephalon, Inc., which provided financing and exclusive licensing for AI-525, an injectable formulation of the hydrophobic drug celecoxib aimed at postoperative pain relief. The company continues to advance Imagify through regulatory review and market development. Acusphere’s technological platform enables controlled porosity and size customization of microspheres for drug delivery applications. The company retains its strategic emphasis on cardiovascular diagnostics while expanding its pipeline with pending clinical trials targeting conditions such as respiration disorders and asthma. The firm continues to strengthen its position through partnerships and regulatory filings to support commercialization in multiple geographies. Acusphere was formerly known as Polymers For Medicine, Inc. until a name change in March 2004. The company remains focused within the specialty pharmaceutical segment of the healthcare industry and targets markets requiring advanced diagnostic imaging and injectable drug formulations. Its leadership includes individuals with extensive pharmaceutical development and regulatory expertise. Acusphere's latest operational and strategic changes highlight its commitment to product innovation and international regulatory expansion to capture growing market opportunities in cardiovascular and respiratory drug development.